Intrexon | XON - مصروفات التشغيل





مصروفات التشغيل تغيير تاريخ
Agenus USD 19.81M 293.94M 2025-12
Alaunos Therapeutics USD 1.19M 148K 2025-09
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
MannKind USD 119.64M 56.29M 2025-12
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Thermo Fisher Scientific USD 9.09B 821M 2026-03
Veracyte USD 116M 7.24M 2025-12
Xencor USD 81.86M 13.35M 2025-12